BIOMAT Database Logo BIOMAT Database Logo

Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis. 2022

Gai Ge, and Zhiya Yang, and Dongmei Li, and Ning Zhang, and Biao Chen, and Dongmei Shi
Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.

Recurrent vulvovaginal candidiasis (RVVC) and vulvovaginal candidiasis (RVVC) are one of the most common gynecological infections, primarily caused by Candida species. Although risk factors of RVVC and VVC have been identified in many studies, antifungal immunological mechanisms are still not fully understood. We performed a 1-year prospective study in a local hospital to monitor 98 patients clinically diagnosed with gynecological Candida infection. The results showed that 20.41% (20/98) are with RVVC, and 79.59% (78/98) patients have VVC. C. albicans accounts for 90% and 96.1% of all strains isolated collected from RVVC and VVC patients, respectively. Antifungal susceptibility testing showed no significant difference in Candida species between RVVC and VVC patients. However, the serum levels of IFN-γ, TNF-α, and IL-17F in the RVVC group were significantly lower than those of the VVC group, while IL-4, IL-6, and IL-10 were higher in the RVVC patients than VVC patients. IL-17A and IL-2 levels were comparable between the two groups. Taken together, our results suggest that the host-immune responses, especially Th1/2 immunity, may play important roles in prognosis of RVVC and VVC.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002175 Candida A genus of yeast-like mitosporic Saccharomycetales fungi characterized by producing yeast cells, mycelia, pseudomycelia, and blastophores. It is commonly part of the normal flora of the skin, mouth, intestinal tract, and vagina, but can cause a variety of infections, including CANDIDIASIS; ONYCHOMYCOSIS; VULVOVAGINAL CANDIDIASIS; and CANDIDIASIS, ORAL (THRUSH). Candida guilliermondii var. nitratophila,Candida utilis,Cyberlindnera jadinii,Hansenula jadinii,Lindnera jadinii,Monilia,Pichia jadinii,Saccharomyces jadinii,Torula utilis,Torulopsis utilis,Monilias
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D002181 Candidiasis, Vulvovaginal Infection of the VULVA and VAGINA with a fungus of the genus CANDIDA. Moniliasis, Vulvovaginal,Vaginitis, Monilial,Candidiasis, Genital,Genital Vulvovaginal Candidiasis,Vaginal Yeast Infection,Vaginal Yeast Infections,Candidiasis, Genital Vulvovaginal,Genital Candidiasis,Infection, Vaginal Yeast,Infections, Vaginal Yeast,Monilial Vaginitis,Vulvovaginal Candidiasis,Vulvovaginal Candidiasis, Genital,Vulvovaginal Moniliasis,Yeast Infection, Vaginal,Yeast Infections, Vaginal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics

Related Publications

Gai Ge, and Zhiya Yang, and Dongmei Li, and Ning Zhang, and Biao Chen, and Dongmei Shi
Recurrent vulvovaginal candidiasis - allergy or immune deficiency?
January 1999, International archives of allergy and immunology,
Gai Ge, and Zhiya Yang, and Dongmei Li, and Ning Zhang, and Biao Chen, and Dongmei Shi
Recurrent vulvovaginal candidiasis.
January 2016, American journal of obstetrics and gynecology,
Gai Ge, and Zhiya Yang, and Dongmei Li, and Ning Zhang, and Biao Chen, and Dongmei Shi
Recurrent vulvovaginal candidiasis.
September 2017, Annals of epidemiology,
Gai Ge, and Zhiya Yang, and Dongmei Li, and Ning Zhang, and Biao Chen, and Dongmei Shi
Recurrent vulvovaginal candidiasis.
January 2006, Missouri medicine,
Gai Ge, and Zhiya Yang, and Dongmei Li, and Ning Zhang, and Biao Chen, and Dongmei Shi
Recurrent vulvovaginal candidiasis.
September 2005, Australian family physician,
Gai Ge, and Zhiya Yang, and Dongmei Li, and Ning Zhang, and Biao Chen, and Dongmei Shi
Recurrent vulvovaginal candidiasis.
March 2005, Australian family physician,
Gai Ge, and Zhiya Yang, and Dongmei Li, and Ning Zhang, and Biao Chen, and Dongmei Shi
Recurrent vulvovaginal candidiasis.
June 2020, BMJ (Clinical research ed.),
Gai Ge, and Zhiya Yang, and Dongmei Li, and Ning Zhang, and Biao Chen, and Dongmei Shi
Recurrent vulvovaginal candidiasis.
August 2001, Current women's health reports,
Gai Ge, and Zhiya Yang, and Dongmei Li, and Ning Zhang, and Biao Chen, and Dongmei Shi
Recurrent vulvovaginal candidiasis.
June 2017, Canadian family physician Medecin de famille canadien,
Gai Ge, and Zhiya Yang, and Dongmei Li, and Ning Zhang, and Biao Chen, and Dongmei Shi
Managing Recurrent Vulvovaginal Candidiasis.
February 2024, Journal of women's health (2002),
Copied contents to your clipboard!